XML 48 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of Business (Details)
3 Months Ended 9 Months Ended
Jun. 19, 2017
USD ($)
position
Jun. 21, 2016
USD ($)
product
Feb. 01, 2016
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Proceeds from sale of businesses             $ 0 $ 437,875,000  
Contingent purchase price from sale of businesses       $ 143,700,000     143,700,000   $ 143,700,000
Restructuring, Settlement and Impairment Provisions [Abstract]                  
Impairment charge       0   $ 0 329,097,000 0  
Severance and other exits costs $ 5,800,000                
Long-lived assets       $ 709,142,000     709,142,000   $ 1,051,258,000
Decrease in fair value of contingent consideration             11,788,000 $ (13,573,000)  
Discontinued operations, disposed of by sale | Hemostasis Business                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Proceeds from sale of businesses     $ 174,100,000            
Contingent purchase price from sale of businesses     $ 235,000,000            
Not discontinued operations, disposed of by sale | Non-Core ACC Products                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Proceeds from sale of businesses   $ 263,807,000              
Contingent purchase price from sale of businesses   $ 480,000,000              
Number of products sold | product   3              
Payment for release of claims   $ 7,500,000              
Not discontinued operations, discontinuation and market withdrawal | Ionsys                  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                  
Number of positions eliminated | position 57                
Percent of workforce eliminated 15.00%                
Restructuring, Settlement and Impairment Provisions [Abstract]                  
Impairment, severance and other employee costs         $ 276,900,000        
Impairment charge         268,100,000        
Severance and other exits costs         8,800,000        
Impairment of fixed assets         11,400,000        
Long-lived assets         0        
Not discontinued operations, discontinuation and market withdrawal | MDCO-700                  
Restructuring, Settlement and Impairment Provisions [Abstract]                  
Decrease in fair value of contingent consideration         14,700,000        
Contingent consideration, carrying value         0        
Income tax benefit, disposition         23,000,000   $ 23,000,000    
Not discontinued operations, discontinuation and market withdrawal | MDCO-700 | In-process research & development                  
Restructuring, Settlement and Impairment Provisions [Abstract]                  
Impairment of indefinite-lived intangible assets         $ 65,000,000